QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its...

QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529 NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its...